Intensive chemotherapy greatly improved survival for lymphoma patients

Share this content:

Survival improved significantly for persons younger than 60 years with diffuse large B-cell lymphoma, one of the most common and aggressive forms of non-Hodgkin lymphoma, when they underwent intensified immunochemotherapy compared with the standard regimen. These patients were also approximately twice as likely to remain in remission 3 years later.

Groupe d'Etude des Lymphomes de l'Adulte and Amgen funded the open-label randomized trial in which Groupe investigators compared two regimens: dose-intensive rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP), administered in four cycles at 2-week intervals; and eight cycles of standard rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (R-CHOP), administered at 3-week intervals. The 379 subjects were aged 18 to 59 years and had untreated diffuse large B-cell lymphoma.

After a median follow-up of 44 months, the 3-year estimate of event-free survival (no unplanned treatment for lymphoma, no disease progression or recurrence, no death) was 81% for the group receiving intensive-therapy R-ACVBP and 67% for the group receiving standard R-CHOP regimen. Three-year estimates of progression-free survival and overall survival were also higher with R-ACVBP, at 87% vs 73% and 92% vs 84%, respectively. Grade 3-4 hematologic toxic effects were more common in the R-ACVBP group, with a higher proportion of patients experiencing a febrile neutropenic episode (75 of 196, or 38%, compared with 16 of 183, or 9%). Nearly half (42%) of the intensive-therapy patients experienced serious adverse events overall, compared with 15% of the standard-therapy participants.   

The investigators described the toxic effects of the intensive regimen as raised but manageable (The Lancet. 2011;378[9806]:1858-1867). In an accompanying Comment (pp.1828-1829), Julie M. Vose of Nebraska Medical Center in Omaha cautioned that the dose-intense regimen should only be used in patients in whom the expected relapse rate is sufficient to justify the higher toxic effects and cost profile.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs